T1	chemical 31 37	sodium
T2	chemical 38 48	thiopental
T3	disease_or_phenotypic_feature 52 60	cataract
T4	chemical 125 131	oxygen
T5	disease_or_phenotypic_feature 156 169	heart failure
T6	chemical 175 182	biology
T7	disease_or_phenotypic_feature 186 193	obesity
T8	chemical 228 233	Tc-99
T9	chemical 235 244	sestamibi
T10	disease_or_phenotypic_feature 286 313	primary hyperparathyroidism
T11	disease_or_phenotypic_feature 357 376	hyperparathyroidism
T12	chemical 431 438	mineral
T13	disease_or_phenotypic_feature 470 481	visual loss
T14	disease_or_phenotypic_feature 485 517	age-related macular degeneration
T15	disease_or_phenotypic_feature 519 522	AMD
T16	chemical 519 522	AMD
T17	disease_or_phenotypic_feature 532 538	glioma
T18	chemical 550 571	5-aminolevulinic acid
T19	chemical 573 578	5-ALA
T20	chemical 584 595	fluorescein
T21	chemical 596 602	sodium
T22	chemical 713 717	drug
T23	chemical 722 729	alcohol
T24	disease_or_phenotypic_feature 737 744	obesity
T25	disease_or_phenotypic_feature 750 781	borderline personality disorder
T26	chemical 783 796	Tonapofylline
T27	chemical 803 813	antagonist
T28	chemical 817 826	adenosine
T29	disease_or_phenotypic_feature 859 872	heart failure
T30	chemical 874 894	Proteasome inhibitor
T31	chemical 895 905	bortezomib
T32	disease_or_phenotypic_feature 953 968	T-cell leukemia
T33	disease_or_phenotypic_feature 969 977	lymphoma
T34	chemical 1034 1042	antigens
T35	disease_or_phenotypic_feature 1046 1054	melanoma
T36	chemical 1092 1111	signaling molecules
T37	disease_or_phenotypic_feature 1176 1182	cancer
T38	chemical 1192 1203	Sibutramine
T39	chemical 1209 1213	drug
T40	disease_or_phenotypic_feature 1249 1256	obesity
T41	chemical 1296 1303	antigen
T42	chemical 1308 1325	alpha-lactalbumin
T43	disease_or_phenotypic_feature 1391 1413	cystosarcoma phyllodes
T44	chemical 1530 1534	drug
T45	disease_or_phenotypic_feature 1546 1552	cancer
T46	chemical 1603 1609	oxygen
T47	disease_or_phenotypic_feature 1660 1678	prostate carcinoma
T48	chemical 1706 1720	growth hormone
T49	disease_or_phenotypic_feature 1731 1738	obesity
T50	chemical 1777 1784	antigen
T51	disease_or_phenotypic_feature 1803 1826	tuberculous peritonitis
T52	chemical 1828 1837	Bromfenac
T53	chemical 1849 1857	solution
T54	disease_or_phenotypic_feature 1915 1923	cataract
T55	disease_or_phenotypic_feature 1935 1961	pseudoexfoliation syndrome
T56	chemical 1984 1990	saline
T57	disease_or_phenotypic_feature 1995 2008	cholesteatoma
T58	disease_or_phenotypic_feature 2024 2031	obesity
T59	chemical 2043 2047	drug
T60	missed_chemical 414 426;439 450	Oral vitamin supplements
T61	corrected_chemical 414 418;431 450	Oral mineral supplements
R1	treats Arg1:T60 Arg2:T13	
R2	treats Arg1:T60 Arg2:T14	
R3	treats Arg1:T60 Arg2:T15	
R4	treats Arg1:T61 Arg2:T13	
R5	treats Arg1:T61 Arg2:T14	
R6	treats Arg1:T61 Arg2:T15	
T62	corrected_chemical 803 838	antagonist of adenosine A1 receptor
R7	treats Arg1:T26 Arg2:T29	
R8	treats Arg1:T62 Arg2:T29	
T63	corrected_disease_or_phenotypic_feature 953 977	T-cell leukemia/lymphoma
R9	treats Arg1:T30 Arg2:T63	
R10	treats Arg1:T31 Arg2:T63	
R11	treats Arg1:T38 Arg2:T40	
T64	missed_chemical 1892 1908	topical steroids
R12	treats Arg1:T64 Arg2:T55	
T65	corrected_chemical 1828 1863	Bromfenac ophthalmic solution 0.09%
R13	treats Arg1:T65 Arg2:T55	
R14	treats Arg1:T56 Arg2:T57	
R15	treats Arg1:T59 Arg2:T58	
T68	missed_disease_or_phenotypic_feature 915 949	tumor-endothelial cell interaction
R19	treats Arg1:T30 Arg2:T68	
R20	treats Arg1:T31 Arg2:T68	
